Is a new industry watchdog necessary?
In the January/February 2002 issue, PharmaVOICE asked readers if the Food and Drug Administration should collect special user fees from pharmaceutical manufacturers to analyze and disseminate data on new drugs and biologics after they are released into the general population. We wanted to know if post-market surveillance should continue to be a function of the FDA, or should the industry become its own watchdog?
The Time Has Come
John J. Schrogie, M.D., VP, Peri-Approval Research Services, Omnicare Clinical Research
A Complicated Issue
John Kamp, Of Counsel, Wiley Rein & Fielding LLP
The Yeahs Have It
Gerald R. Marschke, Director, The Webster Consulting Group Inc.
Fair and Reasonable
Tracey Meyer, Cardiovascular, District Sales Manager, AstraZeneca
On Equal Funding
Matt Giegerich, President and CEO, CommonHealth
Rita Sweeney, President and Chief Operating Officer, Dorland Sweeney Jones
The Nays Have It
Sandy Buck, Group Copy Supervisor, VP, NCI Advertising